Health
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum.Full enrollment expected in Q2 2026.Toronto, Ontario--(Newsfile Corp. - January 13, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"list","items":[{"val":[{"type":"text","content":"Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.","length":137,"tagName":"p"}]},{"val":[{"type":"text","content":"Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum.","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Full enrollment expected in Q2 2026.","length":36,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":294,"olType":false},{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - January 13, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has surpassed 50% patient enrollment in MAVERIC, its Phase III randomized, double-blind, placebo-controlled, multi-center international trial evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis.","length":568,"tagName":"p"},{"type":"text","content":"Reaching this enrollment milestone represents a key execution and risk-reduction inflection point for Cardiol's lead registrational program and underscores strong investigator interest in advancing new treatment options for this underserved patient population.","length":264,"tagName":"p"},{"type":"text","content":""Surpassing 50% enrollment in MAVERIC is an important milestone for our Phase III program and reflects both the high unmet medical need in recurrent pericarditis and the confidence investigators have in the scientific rationale and rigorous design of this pivotal trial," said Dr. Andrew Hamer, Chief Medical Officer and Head of Research & Development at Cardiol Therapeutics. "More than 15 leading cardiovascular centers across the United States are now actively enrolling patients, and with additional premier sites coming online in Europe and Canada, we are well positioned to sustain recruitment momentum, complete enrollment in Q2 2026, and deliver high-quality clinical data supporting CardiolRx™ as a differentiated oral therapy for this challenging disease."","length":790,"tagName":"p"},{"type":"text","content":"...